MA43347B1 - Compositions et méthodes permettant d'inhiber l'expression du gène de lpa - Google Patents

Compositions et méthodes permettant d'inhiber l'expression du gène de lpa

Info

Publication number
MA43347B1
MA43347B1 MA43347A MA43347A MA43347B1 MA 43347 B1 MA43347 B1 MA 43347B1 MA 43347 A MA43347 A MA 43347A MA 43347 A MA43347 A MA 43347A MA 43347 B1 MA43347 B1 MA 43347B1
Authority
MA
Morocco
Prior art keywords
agents
gene expression
compositions
methods
lpa
Prior art date
Application number
MA43347A
Other languages
English (en)
Other versions
MA43347A (fr
Inventor
Steven Kanner
David Rozema
David Lewis
Lauren Almeida
Darren Wakefield
Vladimir Trubetskoy
Tao Pei
Zhen Li
Aaron Almeida
Original Assignee
Arrowhead Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arrowhead Pharmaceuticals Inc filed Critical Arrowhead Pharmaceuticals Inc
Publication of MA43347A publication Critical patent/MA43347A/fr
Publication of MA43347B1 publication Critical patent/MA43347B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3517—Marker; Tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Des agents d'interférence d'arn (arni) et des conjugués d'agents d'arni pour inhiber l'expression du gène de la lpa (apo (a)) sont décrits. Des compositions pharmaceutiques comprenant un ou plusieurs agents arni lpa, éventuellement avec un ou plusieurs agents thérapeutiques supplémentaires, sont également décrites. La délivrance des agents arni lpa décrits aux cellules hépatiques in vivo permet d'inhiber l'expression du gène lpa et le traitement des maladies cardiovasculaires et cardiovasculaires.
MA43347A 2015-10-01 2017-04-06 Compositions et méthodes permettant d'inhiber l'expression du gène de lpa MA43347B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562235816P 2015-10-01 2015-10-01
US201662346304P 2016-06-06 2016-06-06
US201662383221P 2016-09-02 2016-09-02
PCT/US2016/054729 WO2017059223A2 (fr) 2015-10-01 2016-09-30 Compositions et méthodes permettant d'inhiber l'expression du gène de lpa

Publications (2)

Publication Number Publication Date
MA43347A MA43347A (fr) 2018-08-08
MA43347B1 true MA43347B1 (fr) 2021-11-30

Family

ID=58424351

Family Applications (1)

Application Number Title Priority Date Filing Date
MA43347A MA43347B1 (fr) 2015-10-01 2017-04-06 Compositions et méthodes permettant d'inhiber l'expression du gène de lpa

Country Status (36)

Country Link
US (4) US9932586B2 (fr)
EP (2) EP4029941A1 (fr)
JP (5) JP6991966B2 (fr)
KR (3) KR102728481B1 (fr)
CN (1) CN108368506A (fr)
AU (3) AU2016331084B2 (fr)
CA (1) CA3000397A1 (fr)
CL (1) CL2018000803A1 (fr)
CO (1) CO2018003678A2 (fr)
CR (1) CR20180231A (fr)
CY (1) CY1125263T1 (fr)
DK (1) DK3356529T3 (fr)
EA (1) EA038478B1 (fr)
ES (1) ES2896298T3 (fr)
HR (1) HRP20211410T1 (fr)
HU (1) HUE055942T2 (fr)
IL (3) IL258333B (fr)
JO (2) JOP20160211B1 (fr)
LT (1) LT3356529T (fr)
MA (1) MA43347B1 (fr)
MX (2) MX2018003833A (fr)
MY (1) MY195796A (fr)
PE (1) PE20181139A1 (fr)
PH (1) PH12018500713A1 (fr)
PL (1) PL3356529T3 (fr)
PT (1) PT3356529T (fr)
RS (1) RS62523B1 (fr)
SG (1) SG10202008530TA (fr)
SI (1) SI3356529T1 (fr)
SM (1) SMT202100622T1 (fr)
TN (1) TN2018000094A1 (fr)
TW (4) TWI836693B (fr)
UA (1) UA121998C2 (fr)
UY (1) UY36926A (fr)
WO (1) WO2017059223A2 (fr)
ZA (1) ZA202106265B (fr)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7718133B2 (en) 2003-10-09 2010-05-18 3M Innovative Properties Company Multilayer processing devices and methods
US10246709B2 (en) * 2016-03-07 2019-04-02 Arrowhead Pharmaceuticals, Inc. Targeting ligands for therapeutic compounds
JP6989521B2 (ja) 2016-09-02 2022-01-05 アローヘッド ファーマシューティカルズ インコーポレイテッド 標的化リガンド
RS63836B1 (sr) 2017-04-05 2023-01-31 Silence Therapeutics Gmbh Proizvodi i sastavi
KR20200024793A (ko) * 2017-07-06 2020-03-09 애로우헤드 파마슈티컬스 인코포레이티드 알파-ENaC의 발현을 억제하기 위한 RNAi 작용제 및 사용 방법
TN2020000039A1 (en) * 2017-09-11 2021-10-04 Arrowhead Pharmaceuticals Inc Rnai agents and compositions for inhibiting expression of apolipoprotein c-iii (apoc3)
PE20201287A1 (es) * 2017-09-14 2020-11-24 Arrowhead Pharmaceuticals Inc Agentes de iarn y composiciones para inhibir la expresion de la angiopoyetina tipo 3 (angptl3) y metodos de uso
US11110180B2 (en) 2017-10-04 2021-09-07 Avidity Biosciences Inc. Nucleic acid-polypeptide compositions and uses thereof
JP7473472B2 (ja) * 2017-10-17 2024-04-23 アローヘッド ファーマシューティカルズ インコーポレイテッド アシアロ糖タンパク質受容体１の発現を阻害するためのＲＮＡｉ剤および組成物
EP3483270A1 (fr) * 2017-11-13 2019-05-15 Silence Therapeutics GmbH Produits et compositions
CA3081905C (fr) * 2017-11-13 2023-10-03 Silence Therapeutics Gmbh Acides nucleiques permettant d'inhiber l'expression de lpa dans une cellule
IL281597B1 (en) * 2018-09-19 2026-05-01 Arrowhead Pharmaceuticals Inc RNAI agents for suppressing 17 beta-HSD type 13 expression, (HASD17B13), their compositions and uses
PH12021550801B1 (en) * 2018-11-13 2024-04-26 Silence Therapeutics Gmbh Nucleic acids for inhibiting expression of lpa in a cell
CA3142283A1 (fr) * 2019-06-06 2020-12-10 Avidity Biosciences, Inc. Compositions d'acide nucleique-polypeptide et utilisations de celles-ci
EP3983077A4 (fr) * 2019-06-17 2023-12-20 Alnylam Pharmaceuticals, Inc. Administration d'oligonucléotides au striatum
CN112442499B (zh) * 2019-08-30 2026-03-10 恩康药业科技（广州）有限公司 一种抑制MCM7的siRNA、组合物及其应用
AU2020399636A1 (en) * 2019-12-09 2022-06-02 Amgen Inc. RNAi constructs and methods for inhibiting LPA expression
JP2023519215A (ja) * 2020-03-23 2023-05-10 アムジエン・インコーポレーテツド 化学修飾核酸に対するモノクローナル抗体及びその使用
TW202535432A (zh) 2020-08-05 2025-09-16 美商戴瑟納製藥股份有限公司 抑制lpa表現之組合物及方法
JP2023545502A (ja) * 2020-10-16 2023-10-30 サノフイ リポタンパク質（ａ）を阻害するためのｒｎａ組成物および方法
CA3199678A1 (fr) 2020-11-05 2022-05-12 Amgen Inc. Procede de traitement de maladie cardiovasculaire atherosclereuse avec des constructions d'arni ciblant le gene lpa
WO2022121959A1 (fr) * 2020-12-09 2022-06-16 纳肽得有限公司 Molécule d'arnsi et son application dans le traitement de maladies des artères coronaires
US20250304966A1 (en) 2020-12-23 2025-10-02 Argonaute RNA Limited Treatment of cardiovascular disease
US20250034561A1 (en) * 2021-02-18 2025-01-30 Oneglobe Holdings Limited Novel Compositions for Conjugating Oligonucleotides and Carbohydrates
EP4355756A4 (fr) 2021-06-18 2025-08-13 Hongene Biotech Corp N-acétylgalactosamine nucléosides fonctionnalisés
JP2024532271A (ja) 2021-08-30 2024-09-05 ホンジーン バイオテック コーポレイション 官能化ｎ－アセチルガラクトサミンアナログ
EP4402263A2 (fr) 2021-09-14 2024-07-24 Argonaute Rna Limited Traitement d'une maladie cardiovasculaire
CN116801886B (zh) * 2021-09-18 2024-12-06 成都心正合医药科技有限公司 Lpa抑制剂及其用途
WO2023088227A1 (fr) 2021-11-16 2023-05-25 上海舶望制药有限公司 Composition et procédé d'inhibition de l'expression de la protéine angiotensinogène (agt)
CN118401539A (zh) 2021-12-15 2024-07-26 兆维生物科技公司 官能化的n-乙酰半乳糖胺类似物
CN118076738A (zh) * 2021-12-16 2024-05-24 上海拓界生物医药科技有限公司 靶向LPA的siRNA及缀合物
CN114703184B (zh) * 2022-03-11 2024-06-18 厦门甘宝利生物医药有限公司 Lpa抑制剂及其用途
JP2025526074A (ja) * 2022-08-11 2025-08-07 エピジェニック・セラピューティクス・プライベイト・リミテッド エピトープ編集標的のための方法およびその使用
CN115851723B (zh) * 2022-10-24 2023-10-03 厦门甘宝利生物医药有限公司 一种抑制lpa基因表达的rna抑制剂及其应用
WO2024118503A1 (fr) 2022-11-28 2024-06-06 Hongene Biotech Corporation Analogues de n-acétylgalactosamine fonctionnalisés
KR20250130686A (ko) * 2023-01-13 2025-09-02 일라이 릴리 앤드 캄파니 치료 올리고뉴클레오티드-함유 제약 조성물 및 그를 사용한 투여 요법
WO2024210530A1 (fr) * 2023-04-03 2024-10-10 Olix Pharmaceuticals, Inc. Agents arni ciblant le gène lpa et leur utilisation
CN121127587A (zh) * 2023-04-24 2025-12-12 上海京新生物医药有限公司 用于抑制LPA表达的RNAi剂及其应用
TW202509024A (zh) 2023-05-19 2025-03-01 大陸商深圳信立泰藥業股份有限公司 一種磺醯胺類化合物及其製備方法和醫藥用途
CN119343449A (zh) * 2023-05-24 2025-01-21 云合智药（苏州）生物科技有限公司 用于抑制angptl3表达的rnai剂及其应用
AU2024280186A1 (en) 2023-05-31 2025-12-04 Tuojie Biotech (Shanghai) Co., Ltd. Dsrna targeting lpa and use thereof
CN121752721A (zh) * 2023-05-31 2026-03-27 箭头药业股份有限公司 用于多聚体RNAi剂缀合物的肝脏递送平台及其使用方法
DE102023115075A1 (de) * 2023-06-07 2024-12-12 B.Braun Avitum Ag Schlauchrollenpumpe
WO2025064821A2 (fr) 2023-09-21 2025-03-27 Ionis Pharmaceuticals, Inc. Composés et procédés d'inhibition de lpa
WO2025082058A1 (fr) * 2023-10-16 2025-04-24 润佳(上海)医药技术有限公司 Arn double brin inhibant l'expression du gène lpa et son utilisation
CN120344664A (zh) * 2023-10-27 2025-07-18 北京安龙生物医药有限公司 靶向脂蛋白a的寡核苷酸及其用途
WO2025103391A1 (fr) * 2023-11-15 2025-05-22 北京加科瑞康医药科技有限公司 Arnsi pour inhiber l'expression génique de lpa, composition le contenant et utilisation associée
CN120020252A (zh) * 2023-11-17 2025-05-20 纳肽得(青岛)生物医药有限公司 抑制LPA表达的siRNA及其用途
WO2025119212A1 (fr) * 2023-12-05 2025-06-12 广东东阳光药业股份有限公司 Nouvelle arnsi double brin, son conjugué et son utilisation
WO2026092650A1 (fr) * 2024-11-01 2026-05-07 迈威(上海)生物科技股份有限公司 Préparation d'arni destinée à inhiber l'expression du gène lpa et utilisation associée
CN120485189B (zh) * 2025-07-16 2025-10-17 北京悦康科创医药科技股份有限公司 靶向调控LPA基因表达的siRNA及其用途

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL9201440A (nl) 1992-08-11 1994-03-01 Univ Leiden Triantennaire clusterglycosiden, hun bereiding en toepassing.
US5599706A (en) 1994-09-23 1997-02-04 Stinchcomb; Dan T. Ribozymes targeted to apo(a) mRNA
JP2002537828A (ja) 1999-03-10 2002-11-12 フォゲン リミティド 細胞への物質のデリバリー
KR100872437B1 (ko) * 2000-12-01 2008-12-05 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. Ｒｎａ 간섭을 매개하는 작은 ｒｎａ 분자
US7227014B2 (en) 2001-08-07 2007-06-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein (a) expression
US7259150B2 (en) * 2001-08-07 2007-08-21 Isis Pharmaceuticals, Inc. Modulation of apolipoprotein (a) expression
EP1613348B1 (fr) 2003-03-12 2010-06-23 The Arizona Board of Regents on Behalf of the University of Arizona Procedes de modulation de l'angiogenese avec des compositions d'apeline
US8084599B2 (en) 2004-03-15 2011-12-27 City Of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
US8658211B2 (en) 2006-08-18 2014-02-25 Arrowhead Madison Inc. Polyconjugates for in vivo delivery of polynucleotides
BRPI0715375A2 (pt) 2006-08-18 2013-06-18 Hoffmann La Roche policonjugados para distribuiÇço in vivo de polinucleotÍdeos
EP2379083B1 (fr) 2008-12-18 2017-08-16 Dicerna Pharmaceuticals, Inc. Agents allongés servant de substrats de dicer et procédés d'inhibition spécifique de l'expression d'un gène
WO2010093788A2 (fr) 2009-02-11 2010-08-19 Dicerna Pharmaceuticals, Inc. Molécules d'arn interférence substrats de dicer multiplexes ayant des séquences de jonction
EP3023495B1 (fr) 2010-02-24 2019-05-08 Arrowhead Pharmaceuticals, Inc. Compositions pour l'administration ciblée d'arnsi
WO2011141703A1 (fr) * 2010-05-12 2011-11-17 Protiva Biotherapeutics Inc. Compositions et procédés pour réduire au silence l'apolipoprotéine b
BR112013013434A2 (pt) * 2010-12-17 2016-08-16 Arrowhead Res Corp metade que tem por alvo modulador fármaco cinético em cacho de galactose para sirna
US8501930B2 (en) 2010-12-17 2013-08-06 Arrowhead Madison Inc. Peptide-based in vivo siRNA delivery system
NZ611656A (en) 2010-12-29 2014-10-31 Arrowhead Res Corp In vivo polynucleotide delivery conjugates having enzyme sensitive linkages
KR20140051357A (ko) 2011-08-26 2014-04-30 애로우헤드 리서치 코오포레이션 Ｉｎ Ｖｉｖｏ 핵산 전달용 폴리(비닐 에스테르) 고분자
MY167390A (en) * 2011-11-18 2018-08-16 Alnylam Pharmaceuticals Inc Rnai agents, compositions and methods of use thereof for treating transthyretin (ttr) associated diseases
AU2012377385A1 (en) 2012-04-18 2014-01-23 Arrowhead Research Corporation Poly(acrylate) polymers for in vivo nucleic acid delivery
HUE051680T2 (hu) * 2012-05-24 2021-03-29 Ionis Pharmaceuticals Inc Apolipoprotein(a) expressziójának módosítására szolgáló eljárások és készítmények
HK1219422A1 (zh) * 2013-02-28 2017-04-07 Immunogen, Inc. 包含细胞结合剂及细胞毒素剂的轭合物
CA2921162A1 (fr) * 2013-05-01 2014-11-06 Ionis Pharmaceuticals, Inc. Composes antisens conjugues et leur utilisation
WO2015021092A1 (fr) 2013-08-07 2015-02-12 Arrowhead Research Corporation Polyconjugués pour l'administration de déclencheurs d'arni à des cellules tumorales in vivo
WO2016149020A1 (fr) * 2015-03-17 2016-09-22 Arrowhead Research Corporation Agents d'interférence arn
SG10202105989WA (en) 2015-05-29 2021-07-29 Arrowhead Pharmaceuticals Inc Compositions and methods for inhibiting gene expression of hif2alpha
JP6896703B2 (ja) * 2015-07-31 2021-06-30 アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ＴＴＲ関連疾患を治療または予防するためのトランスサイレチン（ＴＴＲ）ｉＲＮＡ組成物およびその使用方法
US10246709B2 (en) 2016-03-07 2019-04-02 Arrowhead Pharmaceuticals, Inc. Targeting ligands for therapeutic compounds

Also Published As

Publication number Publication date
US20200263179A1 (en) 2020-08-20
IL258333B (en) 2022-03-01
UY36926A (es) 2017-04-28
IL290566B2 (en) 2023-07-01
US20170096665A1 (en) 2017-04-06
LT3356529T (lt) 2021-12-27
MA43347A (fr) 2018-08-08
WO2017059223A9 (fr) 2017-08-17
IL290566B1 (en) 2023-03-01
EA038478B1 (ru) 2021-09-03
TWI880645B (zh) 2025-04-11
US10662427B2 (en) 2020-05-26
EP3356529B1 (fr) 2021-08-25
TW202449154A (zh) 2024-12-16
JOP20210043A1 (ar) 2021-03-08
CR20180231A (es) 2018-05-31
BR112018006489A2 (pt) 2018-10-09
KR102942707B1 (ko) 2026-03-23
TWI836693B (zh) 2024-03-21
MY195796A (en) 2023-02-21
US20250115907A1 (en) 2025-04-10
DK3356529T3 (da) 2021-11-08
TW202600825A (zh) 2026-01-01
JP2022113835A (ja) 2022-08-04
US9932586B2 (en) 2018-04-03
NZ780687A (en) 2025-06-27
IL300438A (en) 2023-04-01
SMT202100622T1 (it) 2022-01-10
JP7442574B2 (ja) 2024-03-04
HRP20211410T1 (hr) 2021-12-24
JP7116212B2 (ja) 2022-08-09
WO2017059223A3 (fr) 2017-05-11
JP2021087459A (ja) 2021-06-10
CA3000397A1 (fr) 2017-04-06
TWI784934B (zh) 2022-12-01
JOP20160211B1 (ar) 2021-08-17
AU2016331084A1 (en) 2018-04-19
KR102728481B1 (ko) 2024-11-12
EP3356529A2 (fr) 2018-08-08
TN2018000094A1 (en) 2019-07-08
PL3356529T3 (pl) 2021-12-20
MX2022013010A (es) 2022-11-09
KR20180052703A (ko) 2018-05-18
EP3356529A4 (fr) 2019-09-04
CL2018000803A1 (es) 2018-08-31
AU2016331084B2 (en) 2022-09-08
ES2896298T3 (es) 2022-02-24
SI3356529T1 (sl) 2022-01-31
JP6991966B2 (ja) 2022-02-03
IL290566A (en) 2022-04-01
KR20260046241A (ko) 2026-04-06
US20180195070A1 (en) 2018-07-12
AU2022283623A1 (en) 2023-02-02
PH12018500713A1 (en) 2018-10-15
CN108368506A (zh) 2018-08-03
JP2018529732A (ja) 2018-10-11
EA201890864A1 (ru) 2018-09-28
IL300438B1 (en) 2026-03-01
PT3356529T (pt) 2021-11-04
NZ741086A (en) 2023-11-24
KR20240162596A (ko) 2024-11-15
CO2018003678A2 (es) 2018-11-30
HK1259063A1 (en) 2019-11-22
AU2022283623B2 (en) 2025-07-10
HUE055942T2 (hu) 2022-01-28
AU2025242219A1 (en) 2025-10-23
RS62523B1 (sr) 2021-11-30
EP4029941A1 (fr) 2022-07-20
TW201726918A (zh) 2017-08-01
UA121998C2 (uk) 2020-08-25
TW202332769A (zh) 2023-08-16
WO2017059223A2 (fr) 2017-04-06
IL258333A (en) 2018-05-31
ZA202106265B (en) 2023-08-30
JP2024009262A (ja) 2024-01-19
PE20181139A1 (es) 2018-07-17
SG10202008530TA (en) 2020-10-29
CY1125263T1 (el) 2023-03-24
JP2026040461A (ja) 2026-03-09
MX2018003833A (es) 2018-06-18

Similar Documents

Publication Publication Date Title
MA43347A (fr) Compositions et méthodes permettant d'inhiber l'expression du gène de lpa
PH12020500332A1 (en) Rnai agents and compositions for inhibiting expression of apolipoprotein c-iii (apoc3)
PH12020500309A1 (en) Rnai agents and compositions for inhibiting expression of angiopoietin-like 3 (angptl3), and methods of use
WO2018140920A8 (fr) Compositions et méthodes d'inhibition de l'expression génique du facteur xii
HK1203356A1 (en) Pharmaceutical combinations comprising a thionucleotide analog
MX2015001122A (es) Combinaciones farmaceuticas de un inhibidor de cdk4/6 y un inhibidor de b-raf.
PH12012501755A1 (en) Compositions and methods for treating and/or preventing cardiovascular disease
EA201692318A1 (ru) Композиции и способы для ингибирования экспрессии гена альфа-1-антитрипсина
MX2021013582A (es) Composiciones que comprenden agentes biologicamente activos y sales biliares.
MA40791A (fr) Ciblage lysosomal d'enzymes et utilisations associées
JOP20190263A1 (ar) عوامل RNAi لتثبيط التعبير عن Alpha- EnaC وطرق استخدامها
HK1252852A1 (zh) 阻止HIF2α基因表达的组合物及方法
EA201791225A1 (ru) Композиции и способы применения солабегрона с модифицированным высвобождением при симптомах нижних мочевых путей
WO2016100738A3 (fr) Activité antifibrotique d'inhibiteur de gas6
PH12017502081B1 (en) Composition, containing quisqualis indica extract, for preventing or treating prostatic hyperplasia
GB201302343D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods for using the same
WO2016030899A8 (fr) Méthodes de traitement de la sclérose latérale amyotrophique
AU2017260019A1 (en) Valerian composition and related methods
TW201613926A (en) Inhibitors of bruton's tyrosine kinase
CR20200117A (es) Agentes de iarn y composiciones para inhibir la expresión de la angiopoyetina tipo 3 (angptl3) y métodos de uso
EA202090234A1 (ru) СРЕДСТВА РНКи ДЛЯ ИНГИБИРОВАНИЯ ЭКСПРЕССИИ АЛЬФА-ENaC И СПОСОБЫ ПРИМЕНЕНИЯ
EA202090717A1 (ru) СРЕДСТВА И КОМПОЗИЦИИ РНКи ДЛЯ ИНГИБИРОВАНИЯ ЭКСПРЕССИИ АНГИОПОЭТИН-ПОДОБНОГО БЕЛКА 3 (ANGPTL3) И СПОСОБЫ ПРИМЕНЕНИЯ